2025-07-26 - Analysis Report
Okay, here's the analysis of Transmedics Group Inc (TMDX) based on the provided data, structured into a report format.

**Transmedics Group Inc (TMDX) Analysis Report**

**1. Performance Overview**

*   **Ticker:** TMDX
*   **Company Description:** Transmedics Group Inc. is a medical technology company pioneering a next-generation platform for preserving organs for transplantation.
*   **Cumulative Return (TMDX):** 226.59%
*   **Cumulative Return (S&P 500 - VOO):** 71.23%
*   **Absolute Divergence:** 156.0 (TMDX outperformed VOO by 156.0%)
*   **Relative Divergence:** 61.1 (TMDX's outperformance is positioned at the 61.1th percentile of its historical divergence range.)

**Analysis:**

TMDX has significantly outperformed the S&P 500 (VOO) over the analyzed period. The 156.0% absolute divergence indicates substantial excess returns. A relative divergence of 61.1 suggests this level of outperformance, while significant, is within its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2019-2021  | -4.0%   | 63.4%  | -52.0%  | 0.0   | 0.7    |
| 2020-2022  | 140.0%  | 68.3%  | 138.0%  | 0.1   | 2.1    |
| 2021-2023  | 95.0%   | 69.4%  | 77.0%   | 0.2   | 2.7    |
| 2022-2024  | 147.0%  | 82.8%  | 121.0%  | 0.2   | 2.1    |
| 2023-2025  | 108.0%  | 82.8%  | 56.0%   | 0.5   | 3.7    |

**Analysis:**

*   **CAGR:** Demonstrates strong annual growth in recent periods (2020-2025), but it's important to note the high volatility.
*   **MDD:** Exhibits high Maximum Drawdown (MDD), suggesting considerable risk and potential for significant losses.
*   **Alpha:** Consistently positive and high alpha values indicate strong risk-adjusted performance, meaning TMDX is generating returns beyond what would be expected based on its market exposure.
*   **Beta:** Low beta values (ranging from 0.0 to 0.5) suggest that TMDX's price is not strongly correlated with the S&P 500.
*   **Cap(B):** Market capitalization has grown significantly, suggesting increased investor confidence.

**2. Recent Price Action**

*   **Current Price:** $108.12
*   **Previous Close:** $106.79
*   **Price Change:** +1.25% (Indicates a slight upward movement in the most recent trading session.)
*   **5-day Moving Average:** 106.82
*   **20-day Moving Average:** 118.35
*   **60-day Moving Average:** 121.17

**Analysis:**

The stock price is currently below its 20-day and 60-day moving averages, which might suggest a short-term downtrend. The recent price increase is a positive sign, but further observation is needed to confirm a trend reversal.

**3. Market Risk Indicators & Signals**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 30.90 (Approaching oversold territory)
*   **PPO:** -1.18 (Below zero, indicating a potential downtrend)
*   **Hybrid Signal:** cash_69%_Sell 0.7% of holdings (4 shares - Caution - MRI:0.35)
*   **20-day Relative Divergence Change:** -2.7 (Short-term decrease)
*   **Expected Return:** 61.7% (Long-term expectation)

**Analysis:**

*   The low MRI suggests a generally favorable market environment for TMDX.
*   The RSI indicates the stock may be approaching oversold conditions, potentially signaling a buying opportunity.
*   The negative PPO reinforces the short-term downtrend suggested by the moving averages.
*   The hybrid signal suggests a cautious approach, with a recommendation to slightly reduce holdings.
*   The negative change in relative divergence further supports the recent underperformance relative to the S&P 500.
*   The high expected return suggests analysts are optimistic about TMDX's long-term growth potential.

**4. Recent News & Significant Events:**

*   **[2025-07-23]:** Transmedics Group Inc (TMDX) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **[2025-07-24]:** Analysts are discussing Transmedics Group Inc's (TMDX) recent performance and its outlook in the context of industry trends and global economic factors.
*   **[2025-07-22]:** Transmedics Group Inc (TMDX)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-26]:** Market experts highlight both risks and opportunities for Transmedics Group Inc (TMDX), advising investors to monitor recent news and company announcements.

**Analysis:**

Recent news indicates TMDX is experiencing volatility and is subject to market scrutiny. Investors should closely monitor company announcements, industry trends, and regulatory changes to make informed decisions.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 예상 EPS |
|------------|------|---------|
| 2025-05-08 | 0.70 | 0.29    |
| 2025-02-27 | 0.19 | 0.22    |
| 2024-10-28 | 0.12 | 0.29    |
| 2024-07-31 | 0.35 | 0.21    |
| 2024-04-30 | 0.35 | 0.03    |

**Analysis:**

*   TMDX has shown mixed performance regarding its EPS. While the most recent EPS significantly exceeded expectations (0.70 vs. 0.29), previous quarters were a mix of exceeding and missing expectations.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $0.14B    | 61.47%        |
| 2024-12-31 | $0.12B    | 59.21%        |
| 2024-09-30 | $0.11B    | 55.94%        |
| 2024-06-30 | $0.11B    | 60.59%        |
| 2024-03-31 | $0.10B    | 61.91%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-03-31 | $0.27B    | 9.64%   |
| 2024-12-31 | $0.23B    | 3.00%   |
| 2024-09-30 | $0.21B    | 2.01%   |
| 2024-06-30 | $0.19B    | 6.42%   |
| 2024-03-31 | $0.16B    | 7.65%   |

**Analysis:**

*   **Revenue:** The company shows steady revenue growth over the last five quarters.
*   **Profit Margin:** TMDX maintains a consistently high-profit margin, indicating strong profitability.
*   **Equity:** Total Equity has been increasing, signifying a strengthening financial position.
*   **ROE:** The Return on Equity has fluctuated, with a significant increase in the most recent quarter, indicating increased efficiency in generating profits from shareholder equity.

**7. Overall Analysis & Conclusion**

Transmedics Group Inc. (TMDX) demonstrates a complex picture. The company has exhibited strong historical outperformance compared to the S&P 500, driven by high alpha, but also considerable volatility, as evidenced by high MDD. Recent price action suggests a short-term downtrend, although the RSI hints at a potential buying opportunity. The MRI indicates low market risk, but the hybrid signal recommends caution.

TMDX's earnings have been generally positive. Its revenue growth is consistent, and its profit margins are exceptionally high. The increasing equity and recent spike in ROE suggest a financially healthy and improving company.

**Recommendation:**

Given the mixed signals, a balanced approach is warranted. Investors should be aware of the stock's inherent volatility and recent underperformance. Given recent news events and volatility, careful monitoring of company announcements and broader market conditions is crucial.

